Takeda presents new data showing mezagitamab (tak-079) sustained effect on kidney function 18 months after treatment in primary iga nephropathy

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced new interim data from the phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (tak-079), an anti-cd38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin a (iga) nephropathy. data from the study showed that kidney function (egfr) remained stable in patients with iga nephropathy through week 96 – up to 18 months after the last mezagitamab dose.1 the result.
TAK Ratings Summary
TAK Quant Ranking